[(1S,3S,5R,6R,7S,8R,20R,22R,24R,25R,26S,27R,29S,31R,32R,33R)-33-[[(3aR,4S,6S,7S,7aR)-7-acetyloxy-2,2,6-trimethyl-4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yl]oxy]-6,7,25,26-tetraacetyloxy-5,24,31-trimethyl-10-oxo-20-pentyl-2,4,9,21,23,28,30-heptaoxatetracyclo[27.3.1.03,8.022,27]tritriacontan-32-yl] acetate | 116446-45-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [(1S,3S,5R,6R,7S,8R,20R,22R,24R,25R,26S,27R,29S,31R,32R,33R)-33-[[(3aR,4S,6S,7S,7aR)-7-acetyloxy-2,2,6-trimethyl-4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yl]oxy]-6,7,25,26-tetraacetyloxy-5,24,31-trimethyl-10-oxo-20-pentyl-2,4,9,21,23,28,30-heptaoxatetracyclo[27.3.1.03,8.022,27]tritriacontan-32-yl] acetate
• CAS: 116446-45-8
• 化学式: C₅₅H₈₆O₂₄
• 分子量: 1131.27
• InChiKey: MJDIIVVEAGSHNT-HWNJMUEKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  79
• 可旋转键数：
  18
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  276
• 氢给体数：
  0
• 氢受体数：
  24

反应信息

• 作为产物：
  描述：

  (1S,3S,5R,6S,7S,8R,20R,22R,24R,25S,26S,27R,29S,31R,32R,33R)-33-[[(3aR,4S,6S,7S,7aR)-7-hydroxy-2,2,6-trimethyl-4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yl]oxy]-6,7,25,26,32-pentahydroxy-5,24,31-trimethyl-20-pentyl-2,4,9,21,23,28,30-heptaoxatetracyclo[27.3.1.03,8.022,27]tritriacontan-10-one 、 乙酸酐 以 吡啶 为溶剂， 以3 mg的产率得到[(1S,3S,5R,6R,7S,8R,20R,22R,24R,25R,26S,27R,29S,31R,32R,33R)-33-[[(3aR,4S,6S,7S,7aR)-7-acetyloxy-2,2,6-trimethyl-4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yl]oxy]-6,7,25,26-tetraacetyloxy-5,24,31-trimethyl-10-oxo-20-pentyl-2,4,9,21,23,28,30-heptaoxatetracyclo[27.3.1.03,8.022,27]tritriacontan-32-yl] acetate
  参考文献：
  名称：

  Noda, Naoki; Nishi, Masatoshi; Miyahara, Kazumoto, Chemical and pharmaceutical bulletin, 1988, vol. 36, # 5, p. 1707 - 1713

  摘要：

  DOI：

文献信息

• NODA, NAOKI;NISHI, MASATOSHI;MIYAHARA, KAZUMOTO;KAWASAKI, TOSHIO, CHEM. AND PHARM. BULL., 36,(1988) N 5, C. 1707-1713
  作者：NODA, NAOKI、NISHI, MASATOSHI、MIYAHARA, KAZUMOTO、KAWASAKI, TOSHIO

  DOI：——

  日期：——